SIAMAB THERAPEUTICS

ANGEL-FUNDED SIAMAB COMPLETES $202 MILLION EXIT WITH LARGE COMMERCIAL-STAGE BIOPHARMA - TRANSACTION VALIDATES ANTI-TACA THERAPEUTIC APPROACH FOR TREATMENT OF SOLID TUMORS

August 19, 2019